These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12746785)

  • 1. HIV infection in older patients.
    Adeyemi OM; Badri SM; Max B; Chinomona N; Barker D
    Clin Infect Dis; 2003 May; 36(10):1347. PubMed ID: 12746785
    [No Abstract]   [Full Text] [Related]  

  • 2. Durability of clinical responses to anti-HIV therapies.
    Laurence J
    AIDS Read; 2008 Mar; 18(3):120-1. PubMed ID: 18398977
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
    Kan VL
    AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
    [No Abstract]   [Full Text] [Related]  

  • 5. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
    Collini P; Schwab U; Sarfo S; Obeng-Baah J; Norman B; Chadwick D; Bibby D; Bedu-Addo G
    Clin Infect Dis; 2009 Apr; 48(7):988-91. PubMed ID: 19231976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV infection in older patients in the HAART era.
    Grabar S; Weiss L; Costagliola D
    J Antimicrob Chemother; 2006 Jan; 57(1):4-7. PubMed ID: 16284223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
    Hill A; Miralles D; Vangeneugden T; Lefebvre E
    AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy.
    Hashimoto T; Nishio M; Sakai T; Fujimoto K; Sato N; Endo T; Koike T
    Clin Infect Dis; 2006 Jun; 42(11):1653-5. PubMed ID: 16652326
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 14. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
    Hill A; Sabin C
    AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
    [No Abstract]   [Full Text] [Related]  

  • 15. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
    Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
    Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
    Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U
    Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
    Jayaweera DT; Kolber MA; Brill M; Tanner T; Campo R; Rodriguez A; Chu HM; Garg V
    HIV Med; 2004 Sep; 5(5):364-70. PubMed ID: 15369512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.